Abstract: A method for evaluating a plate including a plurality of wells, the method including: an injection step of injecting an evaluation sample including a cell and a test substance into the plurality of wells, the evaluation sample being adjusted in advance so that a foreign matter is generated as a result of cell death caused by the test substance; a counting step of counting the number of wells having the foreign matter among the plurality of wells at a first counting timing at which a first predetermined time has elapsed since the evaluation sample is injected into the plurality of wells; and a determination step of determining that the plate is appropriate when the number of wells having the foreign matter among the plurality of wells is one or more, and determining that the plate is inappropriate when the number of wells having the foreign matter is zero.

Abstract: A method for assessing an assessment target according to an embodiment includes: a step of acquiring statistical information based on at least one color feature quantity with respect to each of a plurality of assessment regions in a plate image corresponding to an image of an assessment plate that holds an assessment target in a plurality of wells provided in the plate; and a step of determining a color of the plurality of assessment regions by using the statistical information. The assessment target includes a tester, the plurality of wells include a test substance well holding the assessment target that further includes a test substance, the plate image includes a plurality of well images corresponding to the plurality of wells, and each of the plurality of assessment regions includes at least one well image corresponding to at least one of the wells.

Abstract: A method for evaluating induced pluripotent stem cells, including providing cultured induced pluripotent stem cells, measuring spontaneous frequency of an organelle having an abnormal nucleic acid structure in the induced pluripotent stem cells, and identifying induced pluripotent stem cells having a spontaneous frequency of not more than a reference value; induced pluripotent stem cells having the spontaneous frequency exceeding the reference value; and a method for selecting induced pluripotent stem cells further including selecting induced pluripotent stem cells having the spontaneous frequency of not more than the reference value, are described. A production method of induced pluripotent stem cells is also described.

Abstract: The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof.

Abstract: The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.

Abstract: The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.

Abstract: The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof.

Abstract: A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A represents hydrogen, or an unsubstituted linear or branched alkyl.

Abstract: A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A represents hydrogen, or an unsubstituted linear or branched alkyl.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: The present invention provides a method for the synthesis of an A-ring synthon phosphine oxide used in the preparation of 19-nor vitamin D compounds, and to novel synthetic intermediates formed during the synthesis. The new method prepares the phosphine oxide from (D)-glucose.

Abstract: Disclosed is an aqueous organopolysiloxane emulsion for use as an adjuvant to hair-care treatment toiletry preparations suitable in respect of the good storage stability and relatively large average diameter of the organopolysiloxane droplets of 0.1 to 1.0 mm despite the high viscosity of the organopolysiloxane and the high content of the organopolysiloxane. The organopolysiloxane emulsion consists of: (A) 70 to 90% by weight of an organopolysiloxane having a viscosity of 1×105 mPa·s or higher; (B) 1 to 15% by weight of a surface active agent; and (C) 5 to 25% by weight of water.

Abstract: A composition for improving calcium metabolism comprising, as an active ingredient, (20S,22R)-22-methyl-1.alpha.,25-dihydroxyvitamin D.sub.3 ; and a method of treating a calcium metabolism disorder in a mammal comprising administering a therapeutically effective amount of (20S,22R)-22-methyl-1.alpha.,25-dihydroxyvitamin D.sub.3.

Abstract: The present invention discloses a novel, labelled vitamin D.sub.3 derivative in which hydrogen atoms on the skeleton portion, i.e. 6- and 19-positions, are substituted with a deuterium atom or a tritium atom, as well as a novel production process of the labelled vitamin D.sub.3 derivative carried out by way of sulfur dioxide addition reaction of a vitamin D.sub.3 derivative. The labelled portion of the novel vitamin D.sub.3 is resistant against in vivo metabolism and make a long period tracing of its pharmacodynamics in a living body possible.

Abstract: There are disclosed 6,19-epidioxyvitamin D.sub.3 derivatives which are represented by the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each a hydrogen atom or a hydroxyl group; when R.sub.1 is a hydrogen atom, R.sub.2 represents a hydroxyl group and R.sub.3 is a hydrogen atom or a hydroxyl group; when both R.sub.1 and R.sub.2 represent a hydroxyl group, R.sub.3 is a hydrogen atom or a hydroxyl group; and when R.sub.1 is a hydroxyl group and R.sub.2 is a hydrogen atom, R.sub.3 represents a hydroxyl group. The compounds are highly capable of inducing differentiation of human myeloid leukemia cells with minimum effects on calcium metabolism and are useful as an agent to treat leukemia.

Abstract: A 24,25-dihydroxycholestane derivatives of the formula ##STR1## wherein A is a steroid residue and R is an aryl group and a process for preparation of the same are disclosed. The derivatives are an intermediate for synthesis of 24,25-dihydroxycholecalciferol having useful physicological activity like that of vitamin D.sub.3. 24,25-Dihydroxycholecalciferol can be produced in an industrially advantageous method via the intermediate which is easily prepared from commercially available starting compounds.

Abstract: A novel vitamin D.sub.3 derivative of the formula ##STR1## (wherein R.sub.1 is hydrogen or a hydroxyl group) which exhibits strong biological activity like that of vitamin D and is useful as a medicine; and a process for producing the same are disclosed.

Abstract: 1.alpha.,2.alpha.-Dihydroxycholecaliciferol having improved vitamin D activities and a process for preparing the same are disclosed.